Aptar Pharma has announced that it entered a partnership with Kali Care in order to address the challenge of monitoring adherence in ophthalmic clinical trials.
The combination of Aptar Pharma’s ophthalmic device expertise and Kali Care’s ground-breaking digital monitoring system for ophthalmic medications is likely to have a significant impact in reducing the costs and complexity of ophthalmic clinical trials.
Silicon Valley-based technology company Kali Care provides a revolutionary sensor technology, which allows clinicians to replace adherence assumptions in clinical trials with collected real-time data. This represents the latest step for Aptar Pharma in the development of drug delivery devices and collaborations in the connected health space.
This strategic collaboration underlines Aptar Pharma’s continuous efforts in breaking new ground in innovative healthcare technologies.
Aptar Pharma’s ability to support complex projects and meet challenging and changing regulatory requirements was recently demonstrated by their collaboration with Allergan on launching the first US Food and Drug Administration (FDA) approved prescription preservative-free ophthalmic multidose product (Restasis MultiDose™).